Literature DB >> 35071781

Differential Receptor Tyrosine Kinase Phosphorylation in the Uterus of Rats Following Developmental Exposure to Tetrabromobisphenol A.

Lysandra Castro1, Jingli Liu1, Linda Yu1, Alanna D Burwell1, Trey O Saddler2, Lindsay A Santiago1, William Xue1, Julie F Foley1, Michael Staup3, Norris D Flagler4, Min Shi5, Linda S Birnbaum1, Dixon Darlene1.   

Abstract

Tetrabromobisphenol A (TBBPA) is a brominated flame retardant that induces endometrial adenocarcinoma and other uterine tumors in Wistar Han rats; however, early molecular events or biomarkers of TBBPA exposure remain unknown. We investigated the effects of TBBPA on growth factor receptor activation (phospho-RTK) in uteri of rats following early-life exposures. Pregnant Wistar Han rats were exposed to TBBPA (0, 0.1, 25, 250 mg/kg/day) via oral gavage on gestation day 6 through weaning of pups (PND 21). Pups were exposed in utero, through lactation, and by daily gavage from PND 22 to PND 90. Uterine horns were collected (at PND 21, PND 33, PND 90) and formalin-fixed or frozen for histologic, immunohistochemical, phospho-RTK arrays, or western blot analysis. At PND 21, the phosphor-RTKs, FGFR2, FGFR3, TRKC and EPHA1 were significantly increased at different treatment concentrations. Several phospho-RTKs were also significantly overexpressed at PND 33 which included epithelial growth factor receptor (EGFR), Fibroblast Growth Factor Receptor 3-4 (FGFR2, FGFR3, FGFR4), insulin-like growth factor receptor 1 (IGF1R), INSR, AXL, MERTK, PDGFRa and b, RET, Tyrosine Kinase with Immunoglobulin Like and EGF Like Domains 1 and 2 (TIE1; TIE2), TRKA, VEGFR2 and 3, and EPHA1 at different dose treatments. EGFR, an RTK overexpressed in endometrial cancer in women, remained significantly increased for all treatment groups at PND 90. Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) and IGF1R were overexpressed at PND 33 and remained increased through PND 90, although ERBB2 was statistically significant at PND 90. The phospho-RTKs, FGFR3, AXL, DTK, HGFR, TRKC, VEGFR1 and EPHB2 and 4 were also statistically significant at PND 90 at different dose treatments. The downstream effector, phospho-MAPK44/42 was also increased in uteri of treated rats. Our findings show RTKs are dysregulated following early life TBBPA exposures and their sustained activation may contribute to TBBPA-induced uterine tumors observed in rats later in life.

Entities:  

Keywords:  Endometrial Adenocarcinoma; Growth Factor Receptors; Tetrabromobisphenol A (TBBPA); Uterus; Wistar Han Rats

Year:  2021        PMID: 35071781      PMCID: PMC8774279          DOI: 10.1177/23978473211047164

Source DB:  PubMed          Journal:  Toxicol Res Appl        ISSN: 2397-8473


  39 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Disruption of estrogen homeostasis as a mechanism for uterine toxicity in Wistar Han rats treated with tetrabromobisphenol A.

Authors:  J Michael Sanders; Sherry J Coulter; Gabriel A Knudsen; June K Dunnick; Grace E Kissling; Linda S Birnbaum
Journal:  Toxicol Appl Pharmacol       Date:  2016-03-15       Impact factor: 4.219

3.  Analysis of covariance using the rank transformation.

Authors:  W J Conover; R L Iman
Journal:  Biometrics       Date:  1982-09       Impact factor: 2.571

Review 4.  The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Authors:  Jennifer L Hsu; Mien-Chie Hung
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

5.  Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins.

Authors:  Rani Kanthan; Jenna-Lynn B Senger; Dana Diudea
Journal:  World J Surg Oncol       Date:  2010-07-19       Impact factor: 2.754

6.  Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.

Authors:  Linda Yu; Katrin Saile; Carol D Swartz; Hong He; Xiaolin Zheng; Grace E Kissling; Xudong Di; Shantelle Lucas; Stanley J Robboy; Darlene Dixon
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

Review 7.  Estrogen and its receptors in cancer.

Authors:  George G Chen; Qiang Zeng; Gary Mk Tse
Journal:  Med Res Rev       Date:  2008-11       Impact factor: 12.944

Review 8.  Mouse models of uterine corpus tumors: clinical significance and utility.

Authors:  Anne M Friel; Whitfield B Growdon; Christopher K McCann; Alexander B Olawaiye; Elizabeth G Munro; John O Schorge; Diego H Castrillon; Russell R Broaddus; Bo R Rueda
Journal:  Front Biosci (Elite Ed)       Date:  2010-06-01

Review 9.  Targeting RTK Signaling Pathways in Cancer.

Authors:  Tarik Regad
Journal:  Cancers (Basel)       Date:  2015-09-03       Impact factor: 6.639

Review 10.  Activating HER2 mutations as emerging targets in multiple solid cancers.

Authors:  Claire M Connell; Gary J Doherty
Journal:  ESMO Open       Date:  2017-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.